2018 American Heart Association Scientific Sessions
The AHA Scientific Sessions 2018 were held on November 10-12, 2018 in Chicago. The conference consisted of presentations on cardiovascular discovery and clinical practice for clinicians, basic scientists, and researchers. Specifically, the conference included a health tech summit, late-breaking science presentations, a keynote session, the 2018 cholesterol clinical practice guidelines, and poster sessions.
In part 1, Dr Miller discusses the recent updates to the 2018 cholesterol treatment guidelines. The guideline updates were presented during AHA 2018.
In second installment of this series, Dr Miller discusses the cost-effectiveness of PCSK9 inhibitors. He explains how the costs of PCSK9 inhibitors impact cholesterol therapy guideline recommendations and he also discusses how costs affect how PCSK9 inhibitors are used in practice.
In the final installment of the AHA conference series, Parag Joshi, MD, explains the major changes of the 2018 cholesterol guidelines and how these cholesterol-lowering drugs can be used in practice for First Report Managed Care readers. He also discusses the cost-effectiveness of PCSK9 inhibitors.
Praluent Cost-Effectiveness Gleaned from Large Outcome Trial
Researchers shared estimates of the long-term cost-effectiveness of the PCSK9 inhibitor alirocumab in patients after an acute coronary syndrome who had elevated low-density lipoprotein cholesterol levels despite use of high-intensity statins.
Nearly 1 in 5 With High Cholesterol in Community Sample Show Genetic Cause
In a community-based cohort of adults with primary high cholesterol, or hypercholesterolemia, the overall presence of an identifiable genetic cause was 17%.
Decision Aid Guides Patients Through Familial Hypercholesterolemia Treatment Choices
Researchers have developed an online decision aid prototype to support treatment-related discussion between providers and patients with familial hypercholesterolemia.
To Prevent CV Death in At-Risk Patients with Diabetes, Zetia Appears a Cost-Effective Choice
Adding ezetimibe instead of evolocumab to statins to prevent cardiovascular death in patients with type 2 diabetes and established cardiovascular disease appears to be a major cost-savings strategy, researchers found.